IOBT — IO Biotech Cashflow Statement
0.000.00%
- $67.20m
- $7.17m
Annual cashflow statement for IO Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12 | -67.9 | -71.5 | -86.1 | -95.5 |
Depreciation | |||||
Non-Cash Items | 1.94 | 28 | 7.39 | 8.27 | 10.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.148 | -0.776 | 4.24 | 5.87 | 2.21 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -9.96 | -40.6 | -59.7 | -71.7 | -82.3 |
Capital Expenditures | — | -0.153 | -0.69 | -0.323 | -0.044 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | — | -0.153 | -0.69 | -0.323 | -0.044 |
Financing Cash Flow Items | -0.014 | -12.1 | 0 | -3.2 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 5.1 | 253 | 0 | 71.9 | 0 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -4.44 | 208 | -68.9 | 0.603 | -83.2 |